An Acute, Placebo-Controlled, Single-Blind, Crossover, Dose-Response, Exploratory Study to Assess the Effects of New Zealand Pine Bark Extract (Enzogenol®) on Glycaemic Responses in Healthy Participants

Nutrients

CherylS. Gammon¹  WenXin Janice Lim¹  RachelA. Page²  Pamela von Hurst³  Lynne Chepulis⁴ 

[1] School of Health Sciences, Massey University, Auckland 0632, New Zealand;School of Health Sciences, Massey University, Wellington 6021, New Zealand;School of Sport, Exercise and Nutrition, Massey University, Auckland 0632, New Zealand;Waikato Medical Research Centre, University of Waikato, Hamilton 3216, New Zealand;

关键词: new zealand pine bark extract;    enzogenol^®;    proanthocyanidins;    impaired glycaemic control;    hypoglycaemic effects;   

DOI  :  10.3390/nu12020497

来源: DOAJ

【 摘 要 】

An acute, placebo-controlled, single-blind, crossover, dose-response, exploratory study was designed to investigate the hypoglycaemic effects of New Zealand pine bark extract (Enzogenol^®). Twenty-five healthy participants categorised into having a monophasic or complex (biphasic or triphasic) glucose curve shape at the control visit consumed a placebo and Enzogenol^® (50 and 400 mg) on three separate occasions before an oral glucose tolerance test (OGTT). In the monophasic group, 50 and 400 mg of Enzogenol^® significantly reduced the mean glucose incremental area under the curve (iAUC) compared to control 241.3 ± 20.2 vs. 335.4 ± 34.0 mmol/L·min, p = 0.034 and 249.3 ± 25.4 vs. 353.6 ± 31.5 mmol/L·min, p = 0.012, respectively. The 400 mg dose further reduced the percentage increment of postprandial glucose (%PG) 31.4% ± 7.9% vs. 47.5% ± 8.6%, p = 0.010, glucose peak 7.9 ± 0.3 vs. 8.9 ± 0.3 mmol/L, p = 0.025 and 2h-OGTT postprandial glucose (2hPG) 6.1 ± 0.3 vs. 6.7 ± 0.3 mmol/L, p = 0.027. Glucose iAUC was not significantly different in the complex group, except for reductions in %PG 28.7% ± 8.2% vs. 43.4% ± 5.9%, p = 0.012 after 50 mg dose and 27.7% ± 5.4% vs. 47.3% ± 7.2%, p = 0.025 after 400 mg dose. The results suggest that Enzogenol^® may have hypoglycaemic effects in healthy participants, especially those exhibiting monophasic shapes.

【 授权许可】

Unknown